drugset / Trial / NCT07475559
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
NaSequentialOpen-labelTreatment
Summary
This is a Phase I, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, PK/pharmacodynamic (PD) characteristics, and anti-tumor activity of JSKN016HC in subjects with advanced malignant solid tumors.
Timeline
- Start
- 2026-03-01
- Primary completion
- 2028-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JSKN016 | Unknown | 4 mg/kg | Subcutaneous |
| Subject | JSKN016 | Unknown | 5 mg/kg | Subcutaneous |
| Subject | JSKN016 | Unknown | 7 mg/kg | Subcutaneous |
| Subject | JSKN016 | Unknown | 9 mg/kg | Subcutaneous |
Indications
No indication recorded.